This is to inform that due to some circumstances beyond the organizer control, "3rd Edition of International Precision Medicine Conference" (IPMC 2023) scheduled during April 24-26, 2023 in Orlando, Florida, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at precision-medicine@magnusconference.com or call + 1 (702) 988 2320.
The pandemic of COVID-19 highlights the need for public health initiatives in ensuring population health. The spread of SARS-CoV-2 infections has been slowed by large-scale testing, contact tracing, social distancing, and mask usage. Precision medicine emphasizes more precise diagnosis and treatment based on a multiplicity of biomarkers, such as genetic variants, as well as data about the environment, lifestyle, and behaviors of patients. Individual vulnerability and responses to COVID-19 may be better understood using PM methods. PM methods, as they have proven for individuals taking medications like abacavir, may be useful for detecting risks of adverse treatment effects for patients with specific genetic variations, which can assist health-care providers decide whether to change dosages or avoid particular treatments for some people.
Title : Copper (II) complexes as potential anticancer agents
Salah S Massoud, University of Louisiana, United States
Title : Leveraging blockchain technology, edge computing and federated learning to enhance outcomes in precision medicine
Ingrid Vasiliu Feltes, MEDNAX, United States
Title : The new horizons in the patient- centered care for understanding of the reasons of its health problems – Psychosynthesis approach
Ewa Danuta Bialek, Institute of Psychosynthesis, Poland
Title : Hegazy theory for interpretation of human parthenogenesis: A new hypothesis
Abdelmonem Awad Hegazy, Zagazig University, Egypt
Title : Precision Oncology and Personalised Medicine: Innovative Technology for the Treatment of Colorectal Cancer
Huiqin Yang, ICON Clinical Research Ltd, United Kingdom
Title : The role of CD44v6 as a new immunotherapy target for urothelial cancer
Iris Adriana Maria Lodewijk, Institute of Biomedical Research, Spain